Enhancing predictivity and reducing clinical trial failure rates with our extensive range of PDC assays
Clinically relevant models with autologous bloods
Diverse tissue types and gene mutations
Rapid and cost-effective screening
Comprehensive genetic profiling
PDC models from relapsed patients
Drug screening on patient-derived cells
3D Organoid models
Immunotherapy testing
Stratified Medicine assays
Growing network of partnerships with leading cancer hospitals and collaborators, allowing us to offer an ever-expanding range of clinically relevant PDC assays across multiple cancer types
Our Services
Our high-throughput drug screening service utilizes our extensive PDC biobank to test compounds against a diverse range of cancer types and genetic profiles, allowing for earlier, more informed go/no-go decisions.
Flexible screening options (single agent, combination therapy) and access to diverse tissue types with clinically relevant mutations through our partnerships, including:
Reduce late-stage clinical trial failures • Accelerate lead optimization • Identify potential responder patient populations early
Our advanced 3D organoid models incorporate both cancer and stromal cells, providing a more physiologically relevant environment for drug testing.
Models harbor stromal cells • Preservation of tumor heterogeneity • Compatible with various assay endpoints • Models derived from our diverse tissue supplier network, including breast, colorectal, pancreatic, lung, and ovarian cancers • Ability to study drug responses in the context of specific mutations and tumor microenvironments
Improve translation of pre-clinical results to clinical outcomes • Investigate complex tumor-stroma interactions • Evaluate drug penetration and efficacy in 3D structures
We offer unique capability to use matching blood cells (autologous) with the same patient tumor for cutting-edge immuno-oncology research.
Matched tumor and immune cells from the same patient • Customizable co-culture systems • Comprehensive analysis capabilities • Access to matched tumor and immune cells from a wide range of cancer types • Models with varying PD-L1 expression levels and tumor mutational burden
Enhance predictivity of immunotherapy efficacy • Identify optimal combination strategies • Investigate mechanisms of immune evasion
Our Approach
About Us
Dominion Biotech was founded by a team with extensive experience in developing and commercializing novel assays for drug discovery and development in the oncology field. Based in Manchester England, the heart of the industrial revolution, we’ve rapidly expanded our capabilities through strategic partnerships with leading cancer hospitals and collaborators, allowing us to offer an unparalleled diversity of PDC models. These partnerships allow us to continuously expand our PDC offerings, ensuring we can meet the diverse needs of our pharmaceutical partners with models that closely reflect the genetic diversity seen in clinical settings.
Our mission is to revolutionize drug discovery by providing pharmaceutical companies with highly predictive patient-derived cell models and assays, ultimately improving clinical trial success rates and accelerating the development of effective cancer therapies.
Former CEO and co-founder of Imagen Therapeutics. Previously worked in Systems Biology at AstraZeneca. Wellcome Research Fellow. PhD in Cancer Biology from Manchester.
Rod manages laboratory operations and service delivery
Former CEO of Rinicare and Optasia Medical. PhD in Machine Learning and Computer Vision for Breast Cancer from Manchester. Anthony provides strategic leadership and leads on business development.
Anthony provides strategic leadership and leads on business development
We would love to hear from you! Please fill out the form to get in touch with us.
Whether you have a question, partnership opportunity, or would like to learn more about our services, our team is here to assist you. Please provide your contact details and a brief message, and we will get back to you as soon as possible.
Alternatively, please email us at info@dominionbiotech.com